Test Blueprint I. Health Promotion and Disease Prevention – 5% of test content A. Epidemiology (e.g., at-risk populations including cultures; socioeconomic status; age; occupations) B. Prevention (e.g., high risk behaviors; preventive health practices) II. Screening, Early Detection and Diagnosis – 7% of test content C. Risk factors for cancer D. Screening E. Early detection F. Risk Reduction Guidelines G. Diagnostic testing III. Scientific Basis for Practice including Research – 10% of test content H. Carcinogenesis I. Immunology J. Genetics K. Specific cancers (pathophysiology, diagnostic measures, prognosis) L. Classification (tumors, staging, grading) M. Common metastatic sites N. Research Protocols and Clinical Trials IV. Cancer Treatment Modalities – 15% of test content O. Vascular access devices P. Surgery Q. Radiation R. Targeted therapies S. Biotherapy T. Chemotherapy U. Hematopoietic stem cell transplant V. Complementary, alternative and integrative modalities V. Symptom Management – 22% of test content
(risk factors, prevention, education, management, and palliative care using the nursing process) W. Etiology and patterns of symptoms (acute, chronic, late) X. Toxicity and rating scales Y. Alterations in comfort Z. Alterations in protective mechanisms [. Alterations in gastrointestinal function \. Alterations in genitourinary function ]. Alterations in respiratory function ^. Alterations in circulatory function _. Alterations in nutrition `. Alterations in neurological function a. Anatomical and surgical alterations b. Pharmacologic interventions (e.g., antimicrobials; antiemetics; analgesic regimens; psychotropic drugs; growth factors) c. Nonpharmacologic interventions (e.g., heat; massage; imagery) d. Complementary, alternative and integrative modalities VI. Psychosocial Dimensions of Care – 7% of test content e. Cultural, spiritual, and religious diversity f. Financial concerns g. Psychosocial disturbances-alterations h. Anxiety, loss and grief, depression i. Altered body image j. Loss of personal control k. Patient and family support groups l. Learning styles and barriers to learning m. Social relationships n. Coping mechanisms and skills VII. Oncologic Emergencies – 10% of test content
(risk factors, prevention, education and management using the nursing process, including pharmacologic and nonpharmacologic interventions) o. Disseminated intravascular coagulation (DIC) p. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) q. Septic shock r. Tumor lysis syndrome s. Hypersensitivity and/or anaphylaxis t. Hypercalcemia u. Cardiac tamponade v. Spinal cord compression w. Superior vena cava syndrome x. Increased intracranial pressure VIII. Sexuality – 5% of test content
(risk factors, prevention, education, and management using the nursing process, including pharmacologic and nonpharmacologic interventions) y. Reproductive issues (contraception and fertility) z. STD and HIV risk {. Sexual dysfunction (physical and psychological effects) IX. Survivorship – 8% of test content
(concept, education and management using the nursing process) |. Psychosocial, physical and cognitive alterations }. Issues (e.g., financial; employment; insurance; discrimination; family and social support) ~. Acute effects . Late effects . Recurrence and/or secondary malignancies . Rehabilitation and long term follow up X. End of Life Care – 6% of test content
(principles, complex symptom management including pharmacologic and nonpharmacologic interventions, family support and education) . Grief and bereavement process . Reimbursement issues and community resources . Hospice (e.g., principles, settings for care) XI. Professional Performance – 5% of test content . Local, state, and national resources . Application of statement on the scope and standards of oncology nursing practice . Sources of data for evidence-based practice . Education process (teaching and learning principles) . Legal issues . Ethical issues . Patient advocacy . Quality assurance . Professional development . Multidisciplinary collaboration